Funding details
ArrayPatch announced the completion of its seed funding round on 5 November 2026. The company completed a second close that added €1.6 million, bringing its total seed funding to €3.2 million in an oversubscribed round.
The investment round included participation from WakeUp Capital, Spark Venture Funding, Prof Mark Ledwidge, Lakeside Capital, DeepIE Ventures, Enterprise Ireland, and The Boole Investment Syndicate.
Microneedle technology
Based in Cork, Ireland, ArrayPatch is a biotechnology company that develops microneedle patch therapeutics. Its patches dissolve and are composed entirely of medicine, requiring no polymers.
The company's lead platform, named DerMap, delivers drugs through painless patches. Initial applications focus on GLP-1 treatments for obesity and diabetes, alongside therapies for skin cancer and nail fungal infections.
Use of capital and leadership
ArrayPatch will use the proceeds to advance its DerMap platform toward first-in-human clinical studies. The capital will primarily progress GLP-DerMap for obesity and diabetes, while also moving forward programs targeting nail fungal infections and skin cancer.
The company is led by founder and chief executive officer Dr Waleed Faisal, chief financial officer Darren Cunningham, chief development officer Erik Doevendans, and chief operating officer Ryan Bamsey. Neil Thomas and Sean Corkery serve as directors on the board.